Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Promising efficacy of BI-1206, an antibody targeting FcγRIIB in combination with rituximab and acalabrutinib in R/R NHL patients NHL

View Full Paper
Ask AI
Bookmark
Share

Authors

LFLaura FogliattoFCFilipa CordeiroACAugustin Penedo Coello

Discussion

Loading...

Member takes

Overview

Single arm study demonstrates promising efficacy (89% ORR) and manageable adverse events in R/R NHL, suggesting enhanced treatment outcomes.

Key Points

  • Evaluate the safety and efficacy of BI-1206 combined with rituximab and acalabrutinib in R/R NHL patients.
  • Single arm study enrolling 30 R/R NHL patients
  • Initial safety run-in with escalating doses of BI-1206
  • Induction period followed by maintenance therapy for eligible patients
  • Acalabrutinib administered at 100 mg BID over one year.
  • Reported 89% overall response rate (ORR) and 100% disease control rate (DCR)
  • Safety run-in included 12 treated patients, with manageable adverse events
  • Most adverse events were mild or moderate, with no serious events recorded.

Cite This Study

Fogliatto et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db51https://doi.org/10.1182/blood-2025-5349
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial2024 · 9 citations
  2. 2Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study2025
  3. 3Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma2025 · 63 citations
  4. 4Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed / refractory mantle cell lymphoma: phase Ib trial2024 · 7 citations
  5. 5SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPY2023 · 4 citations